Stride (LRN) has stabilized after LMS challenges, with the stock up 34% since January and operational concerns largely ...
Methodology that is not complete, as well as discrepancies regarding the proposed mode of action of lipoxin A4, are significant weaknesses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results